Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Next Previous
X
Search
Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications CNS cancer; Ependymoma; Ewing's sarcoma; Langerhans cell histiocytosis; Lung cancer; Neuroblastoma; Non-Hodgkin's lymphoma; Renal cancer; Rhabdoid tumour; Sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Pediatric MATCH

    • Most Recent Events

    • 26 Sep 2023 Planned End Date changed from 18 Apr 2024 to 22 Sep 2024.
    • 25 May 2023 Primary endpoint has not been met. (Objective response rate (ORR), as per published in the Journal of the National Cancer Institute
    • 25 May 2023 Results assessing Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations, published in the Journal of the National Cancer Institute

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top